Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid t-cell sensitization and rejection of progressive tumor challenges

Cancer Research

Volumn 74, Issue 23, 2014, Pages 6845-6855

  Hoelzinger, Dominique B ^a,b   Dominguez, Ana Lucia ^b   Cohen, Peter A ^a   Gendler, Sra J ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; INTERLEUKIN 9; INTERLEUKIN 9 ANTIBODY; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON CANCER; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE DELETION; GROWTH INHIBITION; IL9 GENE; IMMUNE RESPONSE; IMMUNOMODULATION; LUNG TUMOR; MALE; MOUSE; NONHUMAN; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR REJECTION; TUMOR VOLUME; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PROCEDURES; TRANSGENIC MOUSE;

ADAPTIVE IMMUNITY; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-9; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC;

EID: 84917709115     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0836     Document Type: Article

References (38)

1. Stassen M, Schmitt E, Bopp T. From interleukin-9 to T helper 9 cells. Ann N Y Acad Sci 2012;1247:56-68.
2. Nowak EC, Noelle RJ. Interleukin-9 as a T helper type 17 cytokine. Immunology 2010;131:169-73.
3. Visekruna A, Ritter J, Scholz T, Campos L, Guralnik A, Poncette L, et al. Tc9 cells, a new subset of CD8 T cells, support Th2-mediated airway in flammation. Eur J Immunol 2013;43: 606-18.
4. Goswami R, Kaplan MH. A brief history of IL-9. J Immunol 2011; 186:3283-8.
5. Jabeen R, Kaplan MH. The symphony of the ninth: the development and function of Th9 cells. Curr Opin Immunol 2012;24: 303-7.
6. Noelle RJ, Nowak EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol 2010;10:683-7.
7. Schmitt E, Bopp T. Amazing IL-9: revealing a new function for an "old"cytokine. J Clin Invest 2012;122:3857-9.
8. Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, Imitola J, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3 natural regulatory T cells. Proc Natl Acad Sci U S A 2009;106:12885-90.
9. Eller K, Wolf D, Huber JM, Metz M, Mayer G, McKenzie AN, et al. IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol 2011; 186:83-91.
10. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006;442:997-1002.
11. Yang Z, Zhang B, Li D, Lv M, Huang C, Shen GX, et al. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS ONE 2010;5:e8922.
12. Nowak EC, Weaver CT, Turner H, Begum-Haque S, Becher B, Schreiner B, et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 2009;206:1653-60.
13. Merz H, Houssiau FA, Orscheschek K, Renauld JC, Fliedner A, Herin M, et al. Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood 1991;78:1311-7.
14. Lemoli RM, Fortuna A, Tafuri A, Fogli M, Amabile M, Grande A, et al. Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. Blood 1996;87:3852-9.
15. Lemoli RM, Fortuna A, Tafuri A, Grande A, Amabile M, Martinelli G, et al. Interleukin-9 in human myeloid leukemia cells. Leuk Lymphoma 1997;26:563-73.
16. Lv X, Feng L, Fang X, Jiang Y, Wang X. Overexpression of IL-9 receptor in diffuse large B-cell lymphoma. Int J Clin Exp Pathol 2013;6:911-6.
17. Lv X, Wang X. The role of interleukin-9 in lymphoma. Leuk Lymphoma 2013;54:1367-72.
18. Nagato T, Kobayashi H, Kishibe K, Takahara M, Ogino T, Ishii H, et al. Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients. Clin Cancer Res 2005;11:8250-7.
19. Matsushita K, Arima N, Ohtsubo H, Fujiwara H, Hidaka S, Fukumori J, et al. Frequent expression of interleukin-9 mRNA and infrequent involvement of interleukin-9 in proliferation of primary adult T-cell leukemia cells and HTLV-I infected T-cell lines. Leuk Res 1997;21: 211-6.
20. Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012;18:1248-53.
21. Lu Y, Hong S, Li H, Park J, Hong B, Wang L, et al. Th9 cells promote antitumor immune responses in vivo. J Clin Invest 2012;122:4160-71.
22. Lu Y, Hong B, Li H, Zheng Y, Zhang M,WangS, et al. Tumor-specific IL- 9-producing CD8 Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proc Natl Acad Sci U S A 2014;111:2265-70.
23. Carlsson A, Wingren C, Kristensson M, Rose C, Ferno M, Olsson H, et al. Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc Natl Acad SciUS A 2011;108:14252-7.
24. Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165:5133-42.
25. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol 2001;Chapter 20:Unit 20 2.
26. pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 2000;13:573-83.
27. Forbes EE, Groschwitz K, Abonia JP, Brandt EB, Cohen E, Blanchard C, et al. IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med 2008; 205:897-913.
28. Khan WI, Richard M, Akiho H, Blennerhasset PA, Humphreys NE, Grencis RK, et al. Modulation of intestinal muscle contraction by interleukin-9 (IL-9) or IL-9 neutralization: correlation with worm expulsion in murine nematode infections. Infect Immun 2003;71: 2430-8.
29. Smith SE, Hoelzinger DB, Dominguez AL, Van Snick J, Lustgarten J. Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Cancer Immunol Immunother 2011;60:1775-87.
30. Tan C, Aziz MK, Lovaas JD, Vistica BP, Shi G, Wawrousek EF, et al. Antigen-specific Th9 cells exhibit uniqueness in their kinetics of cytokine production and short retention at the inflammatory site. J Immunol 2010;185:6795-801.
31. Leech MD, Grencis RK. Induction of enhanced immunity to intestinal nematodes using IL-9-producing dendritic cells. J Immunol 2006; 176:2505-11.
32. Turner JE, Morrison PJ, Wilhelm C, Wilson M, Ahlfors H, Renauld JC, et al. IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J Exp Med 2013;210:2951-65.
33. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
34. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010;70:3526-36.
35. Wilhelm C, Hirota K, Stieglitz B, Van Snick J, Tolaini M, Lahl K, et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol 2011;12:1071-7.
36. Vegran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, et al. The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat Immunol 2014;15:758-66.
37. Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A. Innate immune response in Th1-andTh2-dominantmouse strains.Shock 2004;22:460-6.
38. Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA. A randomized, controlled trial to evaluate the effect of an anti-interleukin- 9 monoclonal antibody in adults with uncontrolled asthma. Respir Res 2013;14:93.